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Interaction of the ergot alkaloid dihydroergosine with the binding
of (3H)8-hydroxy-2-(di-n-propylamino)tetralin (3H8-OH-DPAT), a
selective agonist for 5-HT1A binding sites, to hippocampal membra-
nes isolated from human and rat brain was studied. Competition
binding experiments showed that dihydroergosine is a potent dis-
placer of (3H)8-OH-DPAT binding at brain 5-HT1A receptors of both
species. Scatchard analysis of (3H)8-OH-DPAT binding to rat hip-
pocampal membranes in the presence of dihydroergosine revealed
that this ergot compound markedly decreases the number and the
affinity of hippocampal (3H)8-OH-DPAT labelled binding sites. Pre-
incubation of rat hippocampal membranes for 180 min with dihy-
droergosine (2 nmol dm–3) completely prevented the binding of
(3H)8-OH-DPAT (2 nmol dm–3). The data suggest that dihydroergo-
sine is approximately as potent a ligand as 8-OH-DPAT for the hip-
pocampal 5-HT1A receptors from human and rat brains, although
their kinetics of association and dissociation are apparently differ-
ent.
Key words: ergot alkaloid, 5-HT1A receptors, (3H)8-OH-DPAT bind-
ing, hippocampus, human brain, rat brain.
INTRODUCTION
Based on their structural, functional and pharmacological characteris-
tics, 5-hydroxytryptamine (5-HT, serotonin) receptors have been classified
into seven receptor families (5-HT1–7).
1 5-HT1A receptor, a subtype of 5-HT1
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receptor family, was identified almost 20 years ago2,3 and 8-hydroxy-2-(di-
n-propylamino)tetralin (8-OH-DPAT) was soon recognised as its selective
agonist.4 5-HT1A receptor was also the first 5-HT receptor to be fully sequen-
ced.5,6 Electrophysiological studies have demonstrated that activation of
5-HT1A receptors produces hyperpolarisation, i.e. inhibition of neuronal ac-
tivity.7 5-HT1A binding sites are mainly found in limbic areas (hippocampus,
amygdala),8,9,10 in cortex11 and in the midbrain raphe nuclei.10,12,13 The dis-
tribution of mRNA encoding the 5-HT1A receptor corresponds to that of the
5-HT1A binding sites.
14,15 This distribution is consistent with the involve-
ment of 5-HT1A receptors in mood control, as suggested by anxiolytic and
antidepressant properties of many 5-HT1A agonists.
16,17,18 Besides, hippo-
campus is the brain region supposed to be involved in learning and memory
processes.19,20
Ergot alkaloids are drugs that have potent and various effects on the
brain tissue and central nervous system functions.21 One of these drugs, di-
hydroergosine, produces in different animal species behavioural changes
that strongly suggest its antidepressant properties, as well as the involve-
ment of the 5-HT system.22,23,24 We have already demonstrated that dihy-
droergosine inhibited the binding of (3H)5-HT to the whole population of rat
hippocampal 5-HT1 receptors with nanomolar affinity.
25 The aim of the pres-
ent work was to determine the effect of dihydroergosine on the binding of
(3H)8-OH-DPAT to the rat and human hippocampal membranes in order to
verify dihydroergosine's affinity for 5-HT1A receptors. Our data demonstrate
that dihydroergosine possesses a very high affinity for 5-HT1A receptors of
both species.
EXPERIMENTAL
Tissue Preparation
Human tissue was obtained at autopsy, 12 h after death, from two middle-aged
subjects who had no history of neurological or psychiatric illness and were not
known to be taking any psychoactive medication. Male Wistar rats (200 to 250 g)
were killed with a guillotine, brains were removed, placed over ice and the hippo-
campus, was dissected. The tissue, pooled from ten animals or a piece (about 1 g) of
human brain hippocampus was homogenised in 30 volumes of cold Tris buffer (50
mmol dm–3, pH = 7.4 at 25 °C) and centrifuged at 20 000  g for 10 min. The pellet
was resuspended in 20 volumes of the same buffer and incubated in a water bath at
37 °C for 20 min to remove endogenous 5-HT.26 The pellet was washed twice by resu-
spension and centrifugation. The final pellet was resuspended in the incubation buf-
fer (50 mmol dm–3 Tris HCl containing 5.8 mmol dm–3 CaCl2) to obtain about 15 mg
of wet weight rat or human hippocampus (1.2 to 1.4 mg protein per mL of membrane
preparation).
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Binding Assay
Competition binding experiments were performed, with slight modifications, as
described by Peroutka.27 Briefly, 16 to 19 concentrations (10–12 to 10–4 mol dm–3) of
dihydroergosine were used. Each tube contained 0.5 mL of membrane preparation,
0.1 mL of dihydroergosine (dissolved in water) or water, 0.1 mL of (3H)8-OH-DPAT
(final concentration 1 nmol dm–3) and incubation buffer (0.3 mL). Non-specific bind-
ing was determined using 0.01 mmol dm–3 of cold 5-HT, and accounted for 10 to 25%
of total binding.
Saturation binding experiments were performed using different concentrations
(from 0.063 to 8.00 nmol dm–3) of (3H)8-OH-DPAT in the absence (control) or pres-
ence of dihydroergosine (4 nmol dm–3). Non-specific binding was determined using
0.01 mmol dm–3 of cold 5-HT, and accounted for 6% and 34% of the total binding at
0.063 and 8.00 nmol dm–3 of (3H)8-OH-DPAT, respectively. Following preincubation
with dihydroergosine for 15 min, the incubation at 25 °C for 30 min started with the
addition of (3H)8-OH-DPAT and was terminated by rapid filtration through What-
man GF/C filters (pre-soaked overnight in 1% polyethylenimine) to separate bound
from free radioactivity. The filters were washed two times with 5 mL of cold Tris HCl
buffer, transferred to the vials and dried for 1 h at 80 °C. Three mL of the scintilla-
tion cocktail (PPO, POPOP in toluene) was added and the vials were stored at 4 °C
overnight to extract the radioactivity from the filters before liquid scintillation spec-
troscopy at 49% efficiency. All experiments were performed in triplicate and were re-
peated three times.
In one group of experiments, membranes were preincubated with dihydroergo-
sine (2 nmol dm–3) at 25 °C for different lenghts of time (10–180 min) before addition
of (3H)8-OH-DPAT (2 nmol dm–3). Incubation was continued for a further 30 min, as
described in competition experiments. The same data, i.e., the decline of specific
(3H)8-OH-DPAT binding, were used to estimate the time course of dihydroergosine
binding to rat brain membranes.
Protein in the membrane preparation was determined according to Lowry et al. 28
Data Analysis
The data from saturation and displacement binding experiments were analysed
using a computer-based equilibrium binding data (EBDA) program.29 EBDA calcu-
lates the apparent dissociation constant (Kd) and the maximum density of the bind-
ing sites (Bmax) by the Scatchard transformation of saturation binding data. For inhi-
bition experiments, the iterative curve-fitting program was used to calculate the IC50
value (the drug concentration displacing 50% of specific radioligand binding) and the
slope factor (analogous to the Hill coefficient). For the indirect estimation of the time
course of dihydroergosine binding to rat brain membranes, the data were plotted as
ln B0 / (B0 – B) vs. association time, where B0 was the estimated specific binding of
dihydroergosine in the steady state, and B was the estimated specific binding of di-
hydroergosine for the association time shown. Results are expressed as the mean 
standard error.
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Compounds
Dihydroergosine methane sulphonate (Lek, Ljubljana, Slovenia), polyethylen-
imine (Sigma, St.Louis, USA), 8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide
(8-OH-DPAT HBr, Research Biochemicals Inc., Natick, USA), (3H)8-OH-DPAT, spe-
cific activity 40.25 Ci/mmol (Amersham, Buckinghamshire, England).
RESULTS
Increasing concentrations of dihydroergosine (10–12 to 10–4 mol dm–3)
displaced the specific (3H)8-OH-DPAT binding to the human and rat hippo-
campal membranes (Figure 1). The IC50 values were 14.6 (5.2) and 2.00
(0.23) nmol dm–3 for human and rat hippocampal membranes, respectively.
The log-logit transformation of the data yielded a slope of 1.09  0.08 for hu-
man, and 1.21  0.07 for rat brain membranes. In both species, computer as-
sisted analysis of the data showed that dihydroergosine inhibition of
(3H)8-OH-DPAT binding may be adequately explained by a single site model
(P > 0.05, one-site versus two-site model) with an apparent Ki value of 0.73
(0.08) nmol dm–3 for the rat hippocampal membranes.
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Figure 1. Inhibition of specific (3H)8-OH-DPAT (1 nmol dm–3) binding to hippocam-
pal membranes, isolated from human (open circles) and rat (filled circles) brain, by
dihydroergosine. The points are the mean SEM of three separate experiments, each
performed in triplicate.
Saturation curves (Figure 2) indicated that (3H)8-OH-DPAT labelled an
apparently homogenous population of high affinity binding sites from the
rat hippocampus. In the presence of dihydroergosine (4 nmol dm–3), the bin-
ding of (3H)8-OH-DPAT was drastically reduced (Figure 2). Both the maxi-
mum number (Bmax = 0.043 (0.017) pmol/mg protein) and the affinity (Kd =
1.85 (0.15) nmol dm–3) of hippocampal (3H)8-OH-DPAT binding sites were
significantly (P < 0.05, Student t-test) lower in the presence of dihydroer-
gosine when compared with the density (Bmax = 0.185 (0.015) pmol/mg pro-
tein) and affinity (Kd = 0.58 (0.10) nmol dm
–3) of the (3H)8-OH-DPAT bind-
ing sites in the absence of dihydroergosine (controls).
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Figure 2. Representative Scatchard plots and saturation isotherms (inset) of the spe-
cific (3H)8-OH-DPAT binding to the rat hippocampal membranes in the absence (con-
trol) and in the presence of dihydroergosine (4 nmol dm–3). The points are the means
of triplicate determinations from a typical experiment.
The binding of (3H)8-OH-DPAT (2 nmol dm–3) to the rat hippocampal
membranes was diminished or completely abolished when the membranes
were preincubated with 2 nmol dm–3 of dihydroergosine (Figure 3). The spe-
cific binding of (3H)8-OH-DPAT in the presence of dihydroergosine was
17 200 dpm at time »zero« (i.e., when the 30-min incubation started with ad-
dition of membranes). This is 54.7% lower than the specific binding of
(3H)8-OH-DPAT obtained in the absence of dihydroergosine (37 969 dpm),
indicating that the latter drug inhibits the same percent of specific
(3H)8-OH-DPAT (2 nmol dm–3) binding. From the data presented in Figure 3
it was calculated that fifty percent of this initially observed (3H)8-OH-DPAT
binding in the presence of dihydroergosine had declined when the membra-
nes were preincubated for 23.9 min with 2 nmol dm–3 of dihydroergosine.
Three hours preincubation with dihydroergosine induced a complete inhibi-
tion of (3H)8-OH-DPAT binding. If we estimate the binding of dihydroergo-
sine from the decline of specifically bound (3H)8-OH-DPAT, we can obtain a
curve showing the association time course of specific dihydroergosine bind-
ing to rat brain membranes, although in the presence of (3H)8-OH-DPAT for
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Figure 3. The binding of (3H)8-OH-DPAT to the rat hippocampal membranes pre-
incubated with dihydroergosine for different lenghts of time (10–180 min) before ad-
dition of the radiolabelled ligand. Time »zero« denotes the time when the incubation
started with addition of membranes, so that both (3H)8-OH-DPAT and dihydroergo-
sine were incubated with the membranes for a further 30 min. Each point is the
mean  SEM of three independent experiments performed in triplicate.
the last 30 min (Figure 4A). Since the preincubation time »zero« (Figure 3)
equals 30 min of incubation with (3H)8-OH-DPAT, but also with dihydro-
ergosine, our data suggest that, at 25 °C, the binding of dihydroergosine
reached a steady state within 150 to 210 min. Thus, we could not have re-
sults showing the association of dihydroergosine to rat brain membranes
during the initial half hour. However, semilogarithmic transformations of
our estimated data yielded linear plots (r = 0.998) consistent with the asso-
ciation to a homogenous class of specific binding sites (Figure 4B).
DISCUSSION
In the present work, we extended and confirmed our previous data sug-
gesting that the potential antidepressant22,23,24 and anxiolytic30 drug, dihydro-
ergosine, binds with high affinity to the hippocampal 5-HT1A binding sites.
Moreover, we have demonstrated for the first time, using (3H)8-OH-DPAT as
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Figure 4. A. Association of dihydroergosine to rat hippocampal membranes estima-
ted indirectly from the decline of specifically bound (3H)8-OH-DPAT (see Figure 3).
Inability of radioligand (2 nmol dm–3) to label the membranes at 180 min (Figure 3)
was taken as the point when the specific binding of dihydroergosine (2 nmol dm–3)
reached a steady state.
B. Semilogarithmic plot of the estimated association data. B0 is the estimated bind-
ing of dihydroergosine in the steady state, and B is the evaluated binding of dihydro-
ergosine for the association time if we take »zero« binding of (3H)8-OH-DPAT, ob-
served when dihydroergosine was preincubated with the membranes for 180 min, as
the point when the specific binding of dihydroergosine reached the steady state.
a selective and specific radioligand for 5-HT1A receptors, that dihydroergo-
sine has a high affinity for this subtype of 5-HT1 binding sites, in both rat
and human hippocampus. This result is in good agreement with nanomolar
affinity obtained for the same binding site in the rat brain using the non-
selective ligand (3H)5-HT in the presence of CGS 12066B and ritanserin to
mask (3H)5-HT binding to 5-HT1B and 5-HT1C receptor subtypes, respecti-
vely.25 Although the concentration of dihydroergosine inhibiting 50% of spe-
cific (3H)8-OH-DPAT binding (IC50) appeared to be slightly higher for the
human than for the rat brain membranes, the competition curves and the
slope factors were very similar, indicating that dihydroergosine was bound
to a single population of receptors. The findings of nanomolar affinity of di-
hydroergosine to 5-HT1A (present work) and 5-HT2 receptors
31 are in agree-
ment with the reports of other authors,32,33 showing that some other ergot
derivatives have also a high affinity to these 5-HT receptors.
Our experiments indicate that dihydroergosine is approximately as potent
a ligand as 8-OH-DPAT34,35 for the hippocampal 5-HT1A receptors, though
the two drugs appear to have completely different kinetic properties. When
the 30-min incubation started simultaneously with equimolar concentrations
of both compounds, the specific binding of (3H)8-OH-DPAT was about 50%
lower than in the absence of dihydroergosine. These results suggest indirectly
that half of the available binding sites were occupied by dihydroergosine.
The association and dissociation of dihydroergosine are rather slow. Namely,
our results demonstrated that the binding of dihydroergosine reached a steady
state within 2.5 and 3.5 hours. This time is even longer than that observed
by Hamblin et al.33 for the association of (3H)dihydroergotamine to rat brain
membranes. However, we had no labelled dihydroergosine, so (3H)8-OH-DPAT
had to be present in the incubation medium for the last 30 min. We could
not therefore have results showing the association of dihydroergosine to rat
brain membranes during the initial half hour of incubation. It has been shown
that another ergopeptine, (3H)dihydroergotamine, is a high-affinity, slowly
dissociating radioligand for 5-HT1B binding sites in rat brain membranes.
33
The data on the association of this radioligand to rat brain membranes have
shown that, at 37 °C, its specific binding reached a steady state within 1 h.
Unlike dihydroergosine and (3H)dihydroergotamine, the association and dis-
sociation of (3H)8-OH- DPAT, as reported by Hall et al.,34 were rapid. At 37 °C,
the binding of this ligand to hippocampal and striatal membranes reached
equilibrium already within 5 to 7 min. The observed kinetic properties of di-
hydroergotamine33 and dihydroergosine (this study) are in accord with our
behavioural studies showing a very prolonged central serotonergic effect of
this drug after a single i.p. injection.23,36
The present study demonstrates a high affinity of dihydroergosine for
the hippocampal postsynaptic 5-HT1A receptors. However, it may be expected
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that this drug is also a high affinity ligand for the presynaptic, i.e., somato-
dendritic, 5-HT1A receptors. Indirect evidence for this presumption is the
finding that dihydroergosine reduces the 5-HT turnover rate,22 which is
supposedly regulated by somatodendritic autoreceptors of the 5-HT1A sub-
type located on the 5-HT cell bodies in the dorsal and median raphe nuclei
of the brain stem.13,17 Behavioural data indicating that dihydroergosine sti-
mulates, in a (–)-propranolol sensitive manner, the 5-HT syndrome in rats,31
shortens the immobility in the forced swim-test,24 possesses antiaggressive
properties,37 produces hypolocomotion22 and hypothermia,41 might addition-
ally suggest that dihydroergosine is a 5-HT1A receptor agonist. Namely, the
mentioned behavioural changes are believed to be mainly produced by the
stimulation of 5-HT1A receptors.
31,38,39,40 At present, however, it remains un-
clear whether this drug exhibits partial or full agonist properties at this re-
ceptor subtype. Our comparative studies 31 imply that the behavioural profile
of this drug differs from the other known partial or full agonists of 5-HT1A
or 5-HT1B/5-HT1A receptor sites. This might be due to the fact that dihydro-
ergosine possesses two components – one stimulating 5-HT1, presumably
5-HT1A, and the other inhibiting 5-HT2 receptors.
31 Our studies in vitro, in-
cluding this study, have shown a high affinity of this drug for both types of
5-HT receptors.25,31
In conclusion, this study has demonstrated that the ergot alkaloid di-
hydroergosine has a high nanomolar affinity for the 5-HT1A receptors from
the hippocampus of human and rat brains, additionally suggesting its po-
tential as an antidepressive and anxiolytic drug.
Acknowledgement. – We thank Mrs I. Fresl and Mrs Z. Ton{eti} for their skilful
technical assistance.
REFERENCES
1. N. M. Barnes and T. Sharp, Neuropharmacology 38 (1999) 1083–1152.
2. N. W. Pedigo, H. I. Yamamura, and D. L. Nelson, J. Neurochem. 36 (1981) 205–
230.
3. D. N. Middlemiss and J. R. Fozard, Eur. J. Pharmacol. 90 (1983) 151–153.
4. S. Hjorth, A. Carlsson, P. Lindberg, D. Sanchez, H. Wikström, L-E. Arvidsson, U.
Hacksell, and J. L. G. Nilsson, J. Neural Transm. 55 (1982) 169–188.
5. B. K. Kobilka, T. Frielle, S. Collins, T. Yang-Feng, T. S. Kobilka, U. Francke, R. J.
Lefkowitz, and M. G. Caron, Nature 329 (1987) 75–77.
6. A. Fargin, J. R. Raymond, M. J. Lohse, B. K. Kobilka, M. G. Caron, and R. J.
Lefkowitz, Nature 335 (1988) 358–360.
7. R. A. Nicoll, R. C. Malenka, and J. A. Kauer, Phys. Rev. 70 (1990) 5123–565.
8. A. Pazos and J. M. Palacios, Brain Res. 346 (1985) 205–230.
9. P. A Blurton and M. D. Wood, J. Neurochem. 46 (1986) 1392–1398.
DIHYDROERGOSINE AND BRAIN 5-HT RECEPTORS 243
10. C. Del Arco, I. Galende, and A. Pazos, Naunyn-Schmiedeberg's Arch. Pharmacol.
347 (1993) 248–256.
11. P. B. Crino, A. B. Vogt, L. Volicer, and R. G. Wiley, J. Pharmacol. Exp. Ther. 252
(1990) 651–656.
12. D. Verge, G. Daval, M. Marcinkiewicz, A. Patey, S. El Mestikawy, H. Gozlan, and
M. Hamon, J. Neurosci. 6 (1986) 3474–3482.
13. C. Sotelo, B. Cgolley, S. El Mestikawy, H. Gozlan, and M. Hamon, Eur. J. Neuro-
sci. 2 (1990) 1144–1154.
14. D. T. Chalmers and S. J. Watson, Brain Res. 561 (1991) 51–60.
15. P. J. W. Burnet, S. L. Eastwood, K. Lacey, and P. J. Harrison, Brain Res. 676 (1995)
157–168.
16. J. Traber and T. Glaser, Trends Pharmacol. Sci. 8 (1987) 432–437.
17. R. Schreiber and J. De Vry, Prog. Neuro-Psychopharmacol. Biol. Psychiat. 17
(1993) 87–104.
18. S. L. Handley, Pharmacol. Ther. 66 (1995) 103–148.
19. G. Rieder, J. Micheau, A. G. M. Lam, E. V. Roloff, S. J. Martin, H. Bridge, L. de
Hoz, B. Poeschel, J. McCulloch, and R. G. M. Morris, Nature Neurosci. 2 (1999)
898–905.
20. S. J. Martin, P. D. Grimwood, and R. G. M. Morris, Annu. Rev. Neurosci. 23 (2000)
649–711.
21. A. Agnoli, G. Crepaldi, P. F. Spano, and M. Trabucchi, Aging Brain and Ergot Al-
kaloids, Raven Press, New York, 1983.
22. D. Peri~i}, H. Manev, S. Levanat, B. Jernej, D. Vuji}, and N. \or|evi}, Psycho-
pharmacology 90 (1986) 112–118.
23. D. Peri~i} and H. Manev, Eur. J. Pharmacol. 137(1987) 123–125.
24. H. Manev and D. Peri~i}, Psychoneuroendocrinology 13 (1988) 465–469.
25. D. Mück-[eler and D. Peri~i}, J. Neural. Transm. 92 (1993) 1–9.
26. D. L. Nelson, A. Herbert, S. Bourgoin, J. Glowinski, and M. Hamon, Mol. Pharma-
col. 14 (1978) 983–995.
27. S. J. Peroutka, J. Neurochem. 47 (1986) 529–570.
28. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, J. Biol. Chem. 193
(1951) 265–275.
29. G. A. McPherson, Computer Programs in Biomedicine 17 (1983) 107–114.
30. D. Peri~i} and A. Tvrdei}, Eur. J. Pharmacol. 235 (1993) 267–274.
31. D. Peri~i} and D. Mück-[eler, Life Sci. 46 (1990) 1331–1342.
32. P. M. Beart, D. McDonald, M. Cincotta, D. J. De Vries, and A. L. Gundlach, Gen.
Pharmacol. 17 (1986) 57–62.
33. M. W. Hamblin, K. Ariani, P. I. Adriaenssens, and R. D. Ciaranello, J. Pharmacol.
Exp. Ther. 243 (1987) 989–1001.
34. M. D. Hall, S. El Mestikawy, M. B. Emerit, L. Pichat, M. Hamon, and H. Gozlan,
J. Neurochem. 44 (1985) 1685–1696.
35. M. Titeler, R. A. Lyon, K. H. Davis, and R. A. Glennon, Biochem. Pharmacol. 36
(1987) 3265–3271.
36. D. Peri~i} and H. Manev, Life Sci. 42 (1988) 2593–2601
37. H. Manev, D. Peri~i}, and D. Mück-[eler, Pharmacol. Biochem. Behav. 32 (1989)
111–115.
38. M. D. Tricklebank, C. Forler, and R. J. Fozard, Eur. J. Pharmacol. 106 (1984)
271–282.
244 D. MÜCK-[ELER AND D. PERI^I]
39. I. Lucki and A. Frazer, Changes in Behavior Associated with Serotonin Receptors
Following Repeated Treatment with Antidepressant Drugs, in: L. S. Seiden and R.
L. Balster (Eds), Behavioural Parmacology: The Current Status, Alan R. Liss, New
York, 1985, pp. 339–357.
40. L. O. Wilkinson and C. T. Dourish, Serotonin and Animal Behavior, in: S. J. Pe-
routka (Ed), Serotonin Receptor Subtypes: Basic and Clinical Aspects, Wiley-Liss,
New York, 1991, pp. 147–210.
41. D. Peri~i}, unpublished work.
SA@ETAK
Vezanje dihidroergozina za 5-HT1A receptore humanog
i {takorskog mozga
Dorotea Mück-[eler i Danka Peri~i}
Istra`en je utjecaj dihidroergozina (alkaloida ra`ene snijeti) na vezanje (3H)8-
hidroksi-2-(di-n-propilamino)tetralina (3H8-OH-DPAT), liganda selektivnog za vezna
mjesta tipa 5-HT1A, za hipokampalne membrane izolirane iz mozga ~ovjeka i {ta-
kora. Pokusi kompeticije vezanja pokazali su da dihidroergozin sna`no potiskuje ve-
zanje (3H)8-OH-DPAT za receptore 5-HT1A iz mozga obiju vrsta. Scatchardova ana-
liza vezanja (3H)8-OH-DPAT za membrane {takorskog hipokampusa u prisutnosti
dihidroergozina pokazala je da taj spoj zna~ajno smanjuje broj i afinitet hipokam-
palnih veznih mjesta obilje`enih s (3H)8-OH-DPAT. Preinkubacija membrana {takor-
skog hipokampusa s dihidroergozinom (2 nmol dm–3) tijekom 180 min inhibirala je
vezanje (3H)8-OH-DPAT (2 nmol dm–3). Rezultati upu}uju da je dihidroergozin pri-
bli`no podjednako sna`an ligand za hipokampalne 5-HT1A receptore iz mozga ~ovje-
ka i {takora kao i 8-OH-DPAT, iako se kinetika njihove asocijacije i disocijacije o~ito
razlikuje.
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